Biomarkers For The Diagnosis And Prognostic Analysis Of Male Infertility
Funder
National Health and Medical Research Council
Funding Amount
$631,370.00
Summary
Male infertility is a common condition, affecting 1 in 15 men. Although a standard semen analysis is often performed to test whether a man is infertile, it is far from definitive. We have developed a new approach, by looking at proteins that are commonly missing from infertile sperm cells. From this analysis, we can definitively diagnose male infertility and are beginning to understand why men are becoming infertile.
Robert McLachlan is an internationally recognised clinician-scientist in male reproductive health. His basic research examines the genetic & endocrine regulation of sperm production. His clinical studies span male fertility regulation, the use of assisted reproductive treatments, and the evidence-based use of androgen replacement. As Director of Andrology Australia, he has a leading national role in professional and community education, developing research capacity and male health advocacy.
Focus On The Uterus: Basic And Translational Research Strategies To Address Key Issues In Women’s Health. Fertility, Infertility, Endometrial And Pregnancy Disorders.
Funder
National Health and Medical Research Council
Funding Amount
$1,085,790.00
Summary
My work focuses on the endometrium, the lining of the uterus, into which the embryo implants to establish pregnancy. When the endometrium does not function correctly, the woman is usually infertile. Other disorders of the endometrium include endometriosis, menstrual bleeding problems and cancer. My studies have defined the molecular basis for much endometrial dysfunction. I am now developing non-invasive tests for these problems and rationales for new treatments.
Treatments that target cancer causing genes called oncogenes have resulted in new treatment paradigms for cancer. We suggest that outcomes of patients with cancer will be further substantially improved by understanding how cancers can overcome resistance to these treatments that develops in many patients. To accelerate the adoption of these and other new treatments for cancer we will also develop new frameworks for clinical trials.
Strategies For Enhancing The Treatment Of Colon Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$590,785.00
Summary
Colorectal cancer is the third leading cause of cancer related death in Australia. Strategies to improve outcomes for these patients are urgently needed. This NHMRC SRF Fellowship will seek to identify new molecules in cancer cells which can be targeted to treat this disease, and to discover genes which can be used to improve patient response to treatment.
Utilization Of Gene-engineered T Cells For Enhancing Cancer Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$761,656.00
Summary
Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells, whilst minimizing toxicity to normal tissue.
New Strategies For Enhancing Chimeric Antigen Receptor (CAR) T Cell Therapy For Cancer
Funder
National Health and Medical Research Council
Funding Amount
$849,540.00
Summary
The role of the immune system in cancer is now recognised as highly important, highlighted by the success of immunotherapy in patients. Yet many patients fail to respond to this form of treatment due to low frequency of lymphocytes present at the tumor site. A new form of immunotherapy involving transfer of gene-modified lymphocytes is a potential way to overcome this problem. This project will explore new strategies to enhance the utility of this approach against blood and solid cancers.
Integrated Basic And Clinical Cardiovascular Research For The Development Of Innovative Approaches To The Treatment Of Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$925,346.00
Summary
Heart failure (HF) is a common cardiovascular problem which causes disabling symptoms and reduces life expectancy. HF is the commonest cause or contributor to hospitalization in people over 65 years. For patients with advanced HF, survival is worse than that for aggresive cancers. At present, for patients with advanced HF and its complications, there are very few treatment options. Over the next 5 years I will conduct a comprehensive series of studies in animal models and in patients to develop ....Heart failure (HF) is a common cardiovascular problem which causes disabling symptoms and reduces life expectancy. HF is the commonest cause or contributor to hospitalization in people over 65 years. For patients with advanced HF, survival is worse than that for aggresive cancers. At present, for patients with advanced HF and its complications, there are very few treatment options. Over the next 5 years I will conduct a comprehensive series of studies in animal models and in patients to develop new treatment options.Read moreRead less
Dr Gilchrist is a reproductive biologist studying factors that regulate the intrinsic quality of unfertilised eggs. He has developed a new form of hormone-free infertility treatment which he will test in a clinical trial over the next 5 years.
There is a need to improve early detection, monitoring of relapse, and treatments for melanoma, to increase long-term survival. My research vision is to use innovative and cutting edge approaches to conduct a range of complementary studies under three broad but inter-related themes: Theme 1 – Genetic predisposition to melanoma in the general population; Theme 2 – Genetic predisposition to melanoma in high-density families; Theme 3 – Somatic aberrations underlying melanoma development.